TY - JOUR
T1 - Promoting Lymphangiogenesis and Lymphatic Growth and Remodeling to Treat Cardiovascular and Metabolic Diseases
AU - Liu, Xiaolei
AU - Cui, Kui
AU - Wu, Hao
AU - Li, Kathryn S.
AU - Peng, Qianman
AU - Wang, Donghai
AU - Cowan, Douglas B.
AU - Dixon, J. Brandon
AU - Sathish Srinivasan, R.
AU - Bielenberg, Diane R.
AU - Chen, Kaifu
AU - Wang, Da Zhi
AU - Chen, Yabing
AU - Chen, Hong
N1 - Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Lymphatic vessels are low-pressure, blind-ended tubular structures that play a crucial role in the maintenance of tissue fluid homeostasis, immune cell trafficking, and dietary lipid uptake and transport. Emerging research has indicated that the promotion of lymphatic vascular growth, remodeling, and function can reduce inflammation and diminish disease severity in several pathophysiologic conditions. In particular, recent groundbreaking studies have shown that lymphangiogenesis, which describes the formation of new lymphatic vessels from the existing lymphatic vasculature, can be beneficial for the alleviation and resolution of metabolic and cardiovascular diseases. Therefore, promoting lymphangiogenesis represents a promising therapeutic approach. This brief review summarizes the most recent findings related to the modulation of lymphatic function to treat metabolic and cardiovascular diseases such as obesity, myocardial infarction, atherosclerosis, and hypertension. We also discuss experimental and therapeutic approaches to enforce lymphatic growth and remodeling as well as efforts to define the molecular and cellular mechanisms underlying these processes.
AB - Lymphatic vessels are low-pressure, blind-ended tubular structures that play a crucial role in the maintenance of tissue fluid homeostasis, immune cell trafficking, and dietary lipid uptake and transport. Emerging research has indicated that the promotion of lymphatic vascular growth, remodeling, and function can reduce inflammation and diminish disease severity in several pathophysiologic conditions. In particular, recent groundbreaking studies have shown that lymphangiogenesis, which describes the formation of new lymphatic vessels from the existing lymphatic vasculature, can be beneficial for the alleviation and resolution of metabolic and cardiovascular diseases. Therefore, promoting lymphangiogenesis represents a promising therapeutic approach. This brief review summarizes the most recent findings related to the modulation of lymphatic function to treat metabolic and cardiovascular diseases such as obesity, myocardial infarction, atherosclerosis, and hypertension. We also discuss experimental and therapeutic approaches to enforce lymphatic growth and remodeling as well as efforts to define the molecular and cellular mechanisms underlying these processes.
KW - atherosclerosis
KW - cardiovascular disease
KW - diabetes
KW - hypertension
KW - myocardial infarction
UR - http://www.scopus.com/inward/record.url?scp=85144591583&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144591583&partnerID=8YFLogxK
U2 - 10.1161/ATVBAHA.122.318406
DO - 10.1161/ATVBAHA.122.318406
M3 - Review article
C2 - 36453280
AN - SCOPUS:85144591583
SN - 1079-5642
VL - 43
SP - E1-E10
JO - Arteriosclerosis, thrombosis, and vascular biology
JF - Arteriosclerosis, thrombosis, and vascular biology
IS - 1
ER -